AOTMiT: Today the Transparency Council will evaluate, among other things, a flu vaccine and a drug for Tourette's syndrome.

During the session, it was planned:

1. Preparation of a position paper on the evaluation of the drug Mizetam (ezetimibum + atorvastatin) in the indication: prevention of cardiovascular events, i.e. as replacement treatment in patients with coronary heart disease (CHD, Coronary Heart Disease) and acute coronary syndrome (ACS, Acute Coronary Syndrome) with a history of CHD control. ACS, Acute Coronary Syndrome) with a history of disease control achieved with concomitant use of single active substances in separate drug products, but at the same doses as in the combination product).
2. Preparation of a position paper on the Efluelda vaccine for the indication: influenza.
3. Preparation of a position paper on the evaluation of the drug Repatha (evolocumabum) under drug program B.101 "Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)".
4. Preparation of a position paper on the appropriateness of issuing approvals for reimbursement of the medicinal product Orap (pimozidum ) for the indication: chronic motor or vocal (vocal) tics, vocal and motor tics syndrome (Giles de la Tourette syndrome), Leigh syndrome.
5. Preparation of a position on the legitimacy of issuing approvals for reimbursement of foodstuffs for special nutritional purposes:
   • TYR Anamix Junior,
   • TYR Anamix Junior LQ,
   • TYR Anamix Infant,
   • TYR Lophlex LQ,
   • TYR Sphere,
   • TYR Gel,
   • TYR Cooler

For the indication: tyrosinemia.

1. Preparation of an opinion on the inclusion in reimbursement of drugs containing the following active substances for indications other than those specified in the SmPC:
   • amisulpride (p.o.),
   • aripiprazole (p.o.), aripiprazole (i.m.),
   • olanzapine (p.o.),
   • quetiapine (p.o.),
   • risperidone (p.o.), risperidone (i.m.)
   • ziprasidone (p.o.),
   • sertindol (p.o.),
   • paliperidone (i.m.)

IN INDICATIONS:

F21- Schizotypal disorder;

F22- Persistent delusional disorder;

F23- Acute and transient psychotic disorders;

F24- Induced delusional disorder;

F25- Schizoaffective disorder;

F28- Other inorganic psychotic disorders;

F29- Indefinite inorganic psychosis.

1. Preparation of an opinion on the inclusion in reimbursement of drugs containing the active substance immunoglobulin in the off-label indication: treatment of patients with generalized stiffness syndrome.
2. Preparation of an opinion on the draft health policy program of local government units co-financed by the EU under the ESF: "Health Policy Program in the field of health promotion for health care workers in the Lower Silesian Province".
3. Preparation of an opinion on the draft health policy program of local government units co-financed by the EU under the ESF: "Health Policy Program titled "Comprehensive diagnostics in the field of fetal alcohol syndrome spectrum in the Lower Silesian Province".
4. Preparation of an opinion on the draft health policy program of local government units co-financed by the EU under the ESF: "Health policy program on prevention of overweight and obesity in the group of children and adolescents in the Lower Silesian Province".

Source: AOTMiT